Repository logo
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.
Repository logo

Repositorio Institucional de la Universidad de Murcia

Repository logoRepository logo
  • Communities & Collections
  • All of DSpace
  • menu.section.collectors
  • menu.section.acerca
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.
  1. Home
  2. Browse by Subject

Browsing by Subject "Aprepitant"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Publication
    Open Access
    Cancer progression and substance P
    (F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología, 2014) Coveñas, Rafael; Muñoz, Miguel
    The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in cancer. After binding to the NK-1 receptor, SP induces tumor cell proliferation, migration of tumor cells (invasion, infiltration and metastasis) and angiogenesis. In contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells, and exert antiangiogenic properties. The induction of apoptosis offers an appropriate method for cancer treatment. The NK-1 receptor can be considered as a target in cancer treatment. A common mechanism for cancer cell proliferation mediated by SP and the NK-1 receptor occurs and NK-1 receptor antagonists are broadspectrum antineoplastic drugs. The NK-1 receptor antagonist aprepitant is used in clinical practice and exerts an antitumor action against a large number of different human tumor cells. In the future, such antitumor action should be tested in human clinical trials.

DSpace software copyright © 2002-2026 LYRASIS

  • Cookie settings
  • Accessibility
  • Send Feedback